Efficacy News and Research

RSS
Salix third quarter total product revenue increases 81% to $146.2 million

Salix third quarter total product revenue increases 81% to $146.2 million

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Micromet third quarter total revenues decrease to $4.5 million

Micromet third quarter total revenues decrease to $4.5 million

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Positive results from ChemoCentryx CCX354 Phase II study on RA

Positive results from ChemoCentryx CCX354 Phase II study on RA

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific reports positive long-term data from PERSEUS clinical program

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma third quarter total revenues increase 26% to $3.9M

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

New results from BioCryst's BCX4208 Phase 2b gout study

New results from BioCryst's BCX4208 Phase 2b gout study

QRxPharma receives date for US pain drug launch, pending approval

QRxPharma receives date for US pain drug launch, pending approval

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

Live virus used in polio vaccine can evolve and infect, warns TAU researcher

Live virus used in polio vaccine can evolve and infect, warns TAU researcher

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

DSM and Svelte Medical Systems enter into license and supply agreement

DSM and Svelte Medical Systems enter into license and supply agreement

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.